Core Insights - The article discusses the efficacy and safety of Tirzepatide for weight reduction in Chinese adults with obesity, based on a clinical trial published in JAMA [2][3]. Group 1: Clinical Trial Results - The SURMOUNT-CN trial demonstrated that participants receiving a 15 mg dose of Tirzepatide lost an average of 17.5% of their body weight (16.1 kg) after 52 weeks [3]. - The trial involved 29 centers in China and included adults with a BMI of 28 or higher, or 24 or higher with at least one weight-related comorbidity [3]. - Weight loss percentages at week 52 for the 10 mg, 15 mg, and placebo groups were 13.6%, 17.5%, and 2.3%, respectively [4]. Group 2: Safety and Side Effects - The most common adverse events during Tirzepatide treatment were gastrointestinal issues, mostly mild to moderate in severity, with less than 5% of patients discontinuing treatment due to side effects [4]. - The trial concluded that weekly doses of 10 mg or 15 mg of Tirzepatide provide statistically and clinically significant weight loss with acceptable safety [4]. Group 3: Market Performance and Sales - Eli Lilly reported Q3 2025 revenue of $17.601 billion, a 54% increase year-over-year, with total revenue for the first nine months of 2025 reaching $45.887 billion (+46%) [5]. - Tirzepatide (Mounjaro and Zepbound) significantly contributed to Eli Lilly's revenue, generating $24.837 billion (+125%) in the first three quarters of 2025 [5][6]. - In the U.S. market, Eli Lilly's GLP-1 market share has surpassed that of Novo Nordisk, with prescription volume shares of 57.9% vs 41.7% as of Q3 [7].

Core Insights - The article discusses the rising global obesity rates and the challenges of weight loss and maintenance, emphasizing the role of high-sugar diets as a significant factor in obesity and metabolic diseases. It highlights the ongoing debate regarding the impact of sweeteners on weight control and gut health [6][7]. Study Findings - A recent randomized controlled trial published in *Nature Metabolism* provides new insights into the use of sweeteners. Conducted by researchers from Maastricht University and the University of Copenhagen, the study indicates that incorporating sweeteners into a healthy diet can help overweight or obese adults maintain weight loss and positively affect gut microbiota [7][9]. - The study involved 341 adults and 38 overweight or obese children over a year. Participants underwent a two-month low-energy diet, losing at least 5% of their weight, followed by a ten-month weight maintenance phase. During this phase, one group replaced high-sugar foods with sweetener-containing foods, while the other group maintained their usual sugar intake. Both groups adhered to a diet where sugar contributed less than 10% of total energy [9]. - After one year, the sweetener group maintained an additional weight loss of 1.6 kg compared to the control group, with a consistent weight difference ranging from 1.0 to 2.1 kg throughout the follow-up. Those strictly following the study protocol experienced a maximum weight loss advantage of 3.7 kg [9]. - The study also revealed that sweeteners positively influenced gut health, with an increase in short-chain fatty acid-related bacteria and microorganisms involved in methane production. Metabolic analyses indicated enhanced gut fermentation processes and beneficial metabolic pathways, including aromatic compound degradation and vitamin synthesis [9]. Safety and Recommendations - While the sweetener group reported more gastrointestinal discomfort, such as abdominal pain and bloating, severe adverse events were rare and not directly linked to the intervention. The study supports the notion that, when used appropriately, sweeteners can aid in weight management and promote beneficial changes in gut microbiota [11]. - The findings provide scientific backing for the role of sweeteners in weight management, suggesting that their use, alongside a healthy diet, can help prevent weight regain. However, it is recommended that sweetener use be personalized and guided by professionals for optimal results [11].

整理 | GLP1减重宝典内容团队 致力于通过细胞重编程延长寿命与健康寿命的生物技术公司 Junevity 宣布完成 1000 万美元最新融资，使其种子轮融资总额达到 2000 万美元。本轮由 Goldcrest Capital 和 Godfrey Capital 领投，资金将主要用于推进公司在 2 型糖尿病与肥胖领域的核心 siRNA（小干扰 RNA）项目 JUN_01，完成 IND 申报前研究，并启动初步临床试验。Junevity 的创始团队此前首次验证，通过抑制单一转录因子即可 在人体细胞模型中实现细胞状态向健康方向的重编程。 前礼来 Eli Lilly 首席市场官、Junevity 顾问 John Bamforth 表示，JUN_01 兼具提升胰岛素敏感性与减重效果，并可做到半年一次给 药，"这一特性有望满足长期代谢管理中对有效性与耐受性并重的临床需求，无论是单独使用还是与 GLP-1 类药物联合，都具有潜在价 值。" 在临床前研究中，JUN_01 被认为是首个能够将代谢状态"回调"为更健康、更年轻水平的候选药物。研究显示，该疗法可降低血糖、改 善胰岛素敏感性、促进体重下降并维持肌肉量。依托 siRN ...

Core Viewpoint - The study indicates that Tirzepatide is more effective than Semaglutide for weight loss in adults with overweight or obesity, as evidenced by higher percentages of participants achieving significant weight loss milestones [3][12]. Study Overview - A total of 18,386 participants were included in the study, with 52% having type 2 diabetes and an average age of 52 years. The average follow-up time was 165 days, with over 50% of participants discontinuing treatment [4]. - The study utilized electronic health records and linked third-party data to track weight changes at three, six, and twelve months [5]. Weight Loss Results - The results showed significant advantages for the Tirzepatide group in weight loss percentages: - Participants losing ≥5% of body weight: Tirzepatide group at approximately 81.8% vs. Semaglutide group at 66.5%, with a risk ratio of 1.76 [8]. - Participants losing ≥10% of body weight: Tirzepatide group at approximately 62.1% vs. Semaglutide group at 37.1%, with a risk ratio of 2.54 [8]. - Participants losing ≥15% of body weight: Tirzepatide group at approximately 42.3% vs. Semaglutide group at 18.1%, with a risk ratio of 3.24 [8]. - Weight changes over time were also notable: - At 3 months, Tirzepatide group lost 5.9% vs. Semaglutide group at 3.6% - At 6 months, Tirzepatide group lost 10.1% vs. Semaglutide group at 5.8% - At 12 months, Tirzepatide group lost 15.3% [10]. Clinical Implications - The study provides important data for understanding the effectiveness of these weight loss medications and may contribute to future clinical guidelines [13]. - Dr. Patricia Rodriguez highlighted that patients using Tirzepatide were more than twice as likely to lose 10% of their weight compared to those using Semaglutide, and three times more likely to lose 15% [14]. - Both medications resulted in significant weight loss, but the risk of gastrointestinal adverse events was similar between the two groups [14].

Core Viewpoint - Obesity is a significant risk factor for cancer, being the second leading preventable cause after smoking, with over 13 types of cancer closely linked to obesity [6]. Group 1: Obesity and Cancer - Obesity accelerates the occurrence and progression of cancer, yet obese patients often show a "protective effect" during immunotherapy, responding better to treatments and having improved survival rates [7]. - A recent study from Vanderbilt University published in *Nature* reveals that inflammatory cytokines induced by obesity stimulate the expression of PD-1 on tumor-associated macrophages (TAM), weakening the immune surveillance against tumors while simultaneously enhancing the efficacy of anti-PD-1 immunotherapy [8][12]. Group 2: Research Findings - In experiments with mice, those on a high-fat diet (HFD) exhibited significant weight gain and metabolic abnormalities, leading to accelerated tumor growth when injected with cancer cells. However, only the HFD group showed notable anti-tumor effects when treated with anti-PD-1 antibodies [11]. - Analysis of immune cells from HFD mice indicated a decrease in specific CD8+ T cells and an increase in macrophages, with significant changes in TAM, including elevated PD-1 expression and altered metabolic states [14][16]. Group 3: Mechanisms and Implications - The study highlights that obesity-related inflammatory factors like INF-γ and TNF-α upregulate PD-1 expression in macrophages through signaling pathways, which in turn suppresses TAM functionality and reduces T cell activation [17]. - This mechanism suggests that anti-PD-1 inhibitors could effectively counteract the suppressive effects of obesity on TAM, thereby enhancing T cell anti-tumor activity in high BMI populations [18]. Group 4: Future Research Directions - Further investigation is needed to explore the roles of other innate immune cells and different dietary structures in the context of tumor immunity and the effects of obesity [18].

Core Viewpoint - Heng Rui Pharmaceutical is actively enhancing its international management team by recruiting senior talents from global pharmaceutical companies, aiming to strengthen its capabilities in the global innovative drug competition landscape [4][9]. Group 1: Leadership Changes - On December 3, Heng Rui announced the appointment of Zhu Guoxin as Senior Vice President, marking another significant step in the company's strategy to attract senior talent from multinational pharmaceutical firms [4]. - Zhu Guoxin has over 30 years of experience in global drug research and development, with expertise spanning various therapeutic areas including diabetes, obesity, and oncology [6]. - Prior to joining Heng Rui, Zhu held a Vice President position at Eli Lilly, overseeing multiple discovery and early development projects [6]. Group 2: Recent Executive Appointments - In September, Heng Rui appointed Hu Xinhui as Vice President and Chief Technology Officer, who has extensive experience in global technology and commercialization from companies like GSK and Merck [8]. - Sun Zhigang joined as Vice President and Chief Quality Officer from Green Leaf Pharmaceutical Group [8]. - Feng Ji was appointed as General Manager and Chief Operating Officer, bringing over 20 years of experience from AstraZeneca [8]. Group 3: Strategic Implications - The recent appointments reflect Heng Rui's strategy to accelerate the internationalization of its management team, enhancing its capabilities in research, production, quality, and commercialization [9]. - The influx of talent from leading pharmaceutical companies indicates a commitment to improving operational efficiency and strategic management within Heng Rui [9].

Core Viewpoint - The article emphasizes the importance of scientific weight management, which should focus on reducing excess body fat while maintaining or even increasing muscle mass to protect overall health [5][7]. Group 1: Weight Management "Three Must-Dos" - First, strictly control energy intake by limiting high-energy density foods, particularly those high in sugar and fats [9][10]. - Second, increase the consumption of foods that are low in calories but high in satiety, such as green and dark vegetables, whole grains, and soy products [11]. - Third, for individuals who are solely overweight and prefer staple foods, it is recommended to gradually reduce the amount of staple foods consumed, ideally by half a liang (approximately 25 grams) per week [13]. Group 2: Weight Management "Four Avoidances" - First, avoid eating too quickly; meals should last at least 20 minutes to prevent excessive energy intake [15]. - Second, avoid overeating by developing a habit of eating until 70-80% full [16]. - Third, avoid late-night meals, as they can disrupt the body's biological clock and increase the risk of obesity [17]. - Fourth, avoid excessive snacking or casual eating, as these can contribute significantly to total daily energy intake [18]. Group 3: Weight Management "One Adjustment" - One adjustment is to scientifically arrange the order of meals, starting with low-energy but high-satiety foods before consuming higher-energy foods, which can help reduce overall food and energy intake [19]. Group 4: National Strategy - The National Health Commission of China has initiated a three-year "Weight Management Year" action plan, aiming to significantly enhance public awareness and skills in weight management by 2026, with a target of reducing the annual obesity rate increase by 10% [27].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 你有没有注意到，冬天似乎更容易变瘦，而到了夏天体重却容易增加？其实，这种现象并非你的错觉！近期，丹麦哥本哈根大学联合瑞典卡罗 林斯卡学院的研究团队发现，季节性的光照时长变化会通过调控进食规律，从而影响人体的能量代谢与脂肪储存。 这项刊登在《Cell Metabolism》的最新成果，让我们看到了无需节食或锻炼也能瘦身的"天然减重新思路"。 一、光照如何成为"隐形减脂教练" 短日照：激活身体的"燃脂开关" 在实验中，科学家们将小鼠分为三组，分别模拟夏季（18小时光照）、冬季（6小时光照）和赤道（12小时光照）的环境。经过13周观察，发 现冬季短日照组（SL）的小鼠体重和脂肪量明显低于另外两组，尤其是高脂饮食的小鼠，脂肪堆积减少最为显著，肝脏中的甘油三酯含量也 下降了约20%。 更令人惊喜的是，短日照组小鼠的能量消耗（EE）呈上升趋势（p=0.061）。这就像身 ...

Core Viewpoint - The article discusses the approval and potential of TQF3250, an oral GLP-1 receptor agonist developed by China National Pharmaceutical Group, for weight management and type 2 diabetes treatment, highlighting the growing global obesity crisis and the need for effective treatments [6][8]. Group 1: TQF3250 Development and Approval - TQF3250 has received FDA approval for clinical trials aimed at weight management and has also been accepted for trials in type 2 diabetes treatment by the NMPA in China [6]. - The drug is designed to selectively activate the cAMP-dependent GLP-1 receptor signaling pathway, promoting insulin secretion while minimizing gastrointestinal side effects, thus offering a differentiated advantage over existing injectable GLP-1 products [8]. Group 2: Global Obesity Trends - The global prevalence of overweight and obesity is projected to rise from 36% in 2000 to 50% by 2030, affecting nearly 3 billion people [6]. - In China, it is estimated that by 2025, 41% of adults will have a BMI ≥ 25 kg/m², with 9% classified as obese, leading to a projected 515 million adults with high BMI by 2030 [6]. Group 3: Health Implications of Obesity - In 2021, approximately 16 million premature deaths among adults were attributed to obesity-related diseases, with chronic non-communicable diseases accounting for 27% of the global disease burden [6]. - About 55% of premature deaths from type 2 diabetes are closely linked to obesity, indicating a significant gap in the supply of effective obesity management and treatment options [6].

整理 | GLP1减重宝典内容团队 加州大学圣迭戈分校的睡眠研究者Atul Malhotra表示，GLP-1类药物的作用不仅限于减重，可能还涉及代谢、炎症甚至神经调节机制。 肥胖是OSA最重要的可控风险因素之一，减重常带来明显改善。NYU Langone睡眠中心的Alcibiades Rodriguez表示："我们经常看到患 者通过传统方式、代谢手术或GLP-1类药物减重后，睡眠呼吸暂停得到改善，甚至完全缓解。"早期，他主要在为糖尿病或减重开具 GLP-1药物的患者中观察到这些改善，如今该药已获批用于OSA，他也将其纳入常规治疗。"一些患者减重后从每晚依赖CPAP，变成几 乎不再需要使用。"研究也在揭示这些药物对睡眠的积极影响可能超越体重因素，为管理代谢、心肺和睡眠健康提供更多思路。 点击关注，追踪最新GLP-1资讯 替尔泊肽获批用于OSA是一个里程碑。这是首个被允许用于睡眠呼吸暂停的GLP-1药物，也是首个专门用于OSA治疗的FDA批准药物。 此前，OSA主要依靠CPAP等机械手段或外科干预。该批准基于SURMOUNT-OSA研究，结果显示在肥胖人群中，替尔泊肽可显著降低 AHI评分，并推动部分患者从重度转 ...